Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post–Cardiac Surgery

Sarah L. Mehringer, Zachary Klick, Jonathan Bain, Elizabeth B. McNeely, Sreekumar - Subramanian, Lawrence J. Pass, Davis Drinkwater, V. Seenu Reddy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Recombinant and plasma-derived factor products, such as activated factor seven (rFVIIa) and four-factor prothrombin complex concentrate (4-factor PCC), have been used off-label for bleeding after cardiac surgery, but little evidence has been published regarding their efficacy and safety. Objective: To determine whether there is a difference in chest tube output in patients who have received 4-factor PCC or rFVIIa for critical postoperative bleeding associated with cardiovascular surgery. Methods: A retrospective chart review was conducted utilizing the electronic medical record system at a 657-bed community, tertiary care hospital in Nashville, Tennessee. Nonpregnant patients ≥18 years of age experiencing significant bleeding during cardiac surgery who received either PCC or rFVIIa perioperatively or postoperatively between April 2015 through December 2016 were eligible for inclusion. Patients were excluded if they received 4-factor PCC or rFVIIa for any indication other than bleeding during cardiac surgery or if they received both agents. Results: Data conclude that there is no significant difference in chest tube output 24 hours postoperatively between patients treated with 4-factor PCC or rFVIIa. There was no difference in bleeding, thromboembolic events, or re-exploration between the rFVIIa and 4-factor PCC groups, but there was a difference in units of fresh frozen plasma administered and hospital length of stay. Conclusion: 4-Factor PCC may be an equally efficacious alternative to rFVIIa for patients experiencing significant bleeding during cardiac surgery. There is no difference in chest tube output; therefore, there is no difference in bleeding—either at 24 hours postoperatively or total.

Original languageEnglish (US)
Pages (from-to)533-537
Number of pages5
JournalAnnals of Pharmacotherapy
Volume52
Issue number6
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Hemorrhage
Chest Tubes
Thoracic Surgery
Length of Stay
Electronic Health Records
Tertiary Healthcare
recombinant FVIIa
prothrombin complex concentrates
Tertiary Care Centers
Safety

Keywords

  • activated factor 7
  • bleeding
  • cardiac surgery
  • PCC
  • thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post–Cardiac Surgery. / Mehringer, Sarah L.; Klick, Zachary; Bain, Jonathan; McNeely, Elizabeth B.; Subramanian, Sreekumar -; Pass, Lawrence J.; Drinkwater, Davis; Reddy, V. Seenu.

In: Annals of Pharmacotherapy, Vol. 52, No. 6, 01.06.2018, p. 533-537.

Research output: Contribution to journalArticle

Mehringer, Sarah L. ; Klick, Zachary ; Bain, Jonathan ; McNeely, Elizabeth B. ; Subramanian, Sreekumar - ; Pass, Lawrence J. ; Drinkwater, Davis ; Reddy, V. Seenu. / Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post–Cardiac Surgery. In: Annals of Pharmacotherapy. 2018 ; Vol. 52, No. 6. pp. 533-537.
@article{433e3283fe724e4f8c74c4dc68ee28ae,
title = "Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post–Cardiac Surgery",
abstract = "Background: Recombinant and plasma-derived factor products, such as activated factor seven (rFVIIa) and four-factor prothrombin complex concentrate (4-factor PCC), have been used off-label for bleeding after cardiac surgery, but little evidence has been published regarding their efficacy and safety. Objective: To determine whether there is a difference in chest tube output in patients who have received 4-factor PCC or rFVIIa for critical postoperative bleeding associated with cardiovascular surgery. Methods: A retrospective chart review was conducted utilizing the electronic medical record system at a 657-bed community, tertiary care hospital in Nashville, Tennessee. Nonpregnant patients ≥18 years of age experiencing significant bleeding during cardiac surgery who received either PCC or rFVIIa perioperatively or postoperatively between April 2015 through December 2016 were eligible for inclusion. Patients were excluded if they received 4-factor PCC or rFVIIa for any indication other than bleeding during cardiac surgery or if they received both agents. Results: Data conclude that there is no significant difference in chest tube output 24 hours postoperatively between patients treated with 4-factor PCC or rFVIIa. There was no difference in bleeding, thromboembolic events, or re-exploration between the rFVIIa and 4-factor PCC groups, but there was a difference in units of fresh frozen plasma administered and hospital length of stay. Conclusion: 4-Factor PCC may be an equally efficacious alternative to rFVIIa for patients experiencing significant bleeding during cardiac surgery. There is no difference in chest tube output; therefore, there is no difference in bleeding—either at 24 hours postoperatively or total.",
keywords = "activated factor 7, bleeding, cardiac surgery, PCC, thrombocytopenia",
author = "Mehringer, {Sarah L.} and Zachary Klick and Jonathan Bain and McNeely, {Elizabeth B.} and Subramanian, {Sreekumar -} and Pass, {Lawrence J.} and Davis Drinkwater and Reddy, {V. Seenu}",
year = "2018",
month = "6",
day = "1",
doi = "10.1177/1060028017752365",
language = "English (US)",
volume = "52",
pages = "533--537",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post–Cardiac Surgery

AU - Mehringer, Sarah L.

AU - Klick, Zachary

AU - Bain, Jonathan

AU - McNeely, Elizabeth B.

AU - Subramanian, Sreekumar -

AU - Pass, Lawrence J.

AU - Drinkwater, Davis

AU - Reddy, V. Seenu

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Recombinant and plasma-derived factor products, such as activated factor seven (rFVIIa) and four-factor prothrombin complex concentrate (4-factor PCC), have been used off-label for bleeding after cardiac surgery, but little evidence has been published regarding their efficacy and safety. Objective: To determine whether there is a difference in chest tube output in patients who have received 4-factor PCC or rFVIIa for critical postoperative bleeding associated with cardiovascular surgery. Methods: A retrospective chart review was conducted utilizing the electronic medical record system at a 657-bed community, tertiary care hospital in Nashville, Tennessee. Nonpregnant patients ≥18 years of age experiencing significant bleeding during cardiac surgery who received either PCC or rFVIIa perioperatively or postoperatively between April 2015 through December 2016 were eligible for inclusion. Patients were excluded if they received 4-factor PCC or rFVIIa for any indication other than bleeding during cardiac surgery or if they received both agents. Results: Data conclude that there is no significant difference in chest tube output 24 hours postoperatively between patients treated with 4-factor PCC or rFVIIa. There was no difference in bleeding, thromboembolic events, or re-exploration between the rFVIIa and 4-factor PCC groups, but there was a difference in units of fresh frozen plasma administered and hospital length of stay. Conclusion: 4-Factor PCC may be an equally efficacious alternative to rFVIIa for patients experiencing significant bleeding during cardiac surgery. There is no difference in chest tube output; therefore, there is no difference in bleeding—either at 24 hours postoperatively or total.

AB - Background: Recombinant and plasma-derived factor products, such as activated factor seven (rFVIIa) and four-factor prothrombin complex concentrate (4-factor PCC), have been used off-label for bleeding after cardiac surgery, but little evidence has been published regarding their efficacy and safety. Objective: To determine whether there is a difference in chest tube output in patients who have received 4-factor PCC or rFVIIa for critical postoperative bleeding associated with cardiovascular surgery. Methods: A retrospective chart review was conducted utilizing the electronic medical record system at a 657-bed community, tertiary care hospital in Nashville, Tennessee. Nonpregnant patients ≥18 years of age experiencing significant bleeding during cardiac surgery who received either PCC or rFVIIa perioperatively or postoperatively between April 2015 through December 2016 were eligible for inclusion. Patients were excluded if they received 4-factor PCC or rFVIIa for any indication other than bleeding during cardiac surgery or if they received both agents. Results: Data conclude that there is no significant difference in chest tube output 24 hours postoperatively between patients treated with 4-factor PCC or rFVIIa. There was no difference in bleeding, thromboembolic events, or re-exploration between the rFVIIa and 4-factor PCC groups, but there was a difference in units of fresh frozen plasma administered and hospital length of stay. Conclusion: 4-Factor PCC may be an equally efficacious alternative to rFVIIa for patients experiencing significant bleeding during cardiac surgery. There is no difference in chest tube output; therefore, there is no difference in bleeding—either at 24 hours postoperatively or total.

KW - activated factor 7

KW - bleeding

KW - cardiac surgery

KW - PCC

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85044087277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044087277&partnerID=8YFLogxK

U2 - 10.1177/1060028017752365

DO - 10.1177/1060028017752365

M3 - Article

AN - SCOPUS:85044087277

VL - 52

SP - 533

EP - 537

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -